Table 1.
Characteristics of “early” (day 4–15) seroconverters as compared to patients who remained sero-negative during the same period
| Patient groups | IgG + n (%) | IgG − n (%) | p-Value (χ2) |
|---|---|---|---|
| Male | 27 (40.9) | 32 (38.6) | 0.770 |
| Female | 39 (59.1) | 51 (61.4) | |
| Age <65 years | 57 (86.4) | 62 (74.7) | 0.078 |
| Age ≥65 years | 9 (13.6) | 21 (25.3) | |
| Co-morbidity | 8 (12.3) | 11 (13.9) | 0.775 |
| No co-morbidity | 57 (87.7) | 68 (86.1) | |
| ICU care | 20 (30.3) | 11 (13.3) | 0.011a |
| No ICU care | 46 (69.7) | 72 (86.7) | |
| Death | 11 (16.7) | 15 (18.1) | 0.822 |
| Survive | 55 (83.3) | 68 (81.9) | |
| O2-therapy | 37 (56.9) | 39 (53.4) | 0.680 |
| No O2-therapy | 28 (43.1) | 34 (46.6) | |
| CS-treated | 52 (78.8) | 58 (69.9) | 0.219 |
| Not CS-treated | 14 (21.2) | 25 (30.1) | |
| Positive RT-PCR | 22 (40.0) | 20 (31.7) | 0.350 |
| Negative RT-PCR | 33 (60.0) | 43 (68.3) | |
| IgG + (all cases) |
IgG − (all cases) |
p-Value (Mann–Whitney) |
|
| Initial lymphocyte (median) × 109/L | 0.74 | 0.73 | 0.824 |
| Lymphocyte nadir (median) × 109/L | 0.23 | 0.28 | 0.315 |
| Peak LDH (median) (IU/L) | 440 | 383 | 0.319 |
IgG: anti-SARS-CoV IgG as detected by indirect immunofluorescence technique. Co-morbidity: malignancy, cirrhosis, chronic renal failure, chronic lung diseases, congestive heart failure, cerebrovascular diseases; ICU: intensive care unit; O2-therapy: oxygen supplement required to maintain oxygen saturation >95%; CS: intravenous high-dose corticosteroid (methylprednisolone); RT-PCR: on respiratory sites specimens and fecal specimens; LDH: lactate dehydrogenase.
a
Statistically significant.